Limiting unnecessary antibiotic use is a major public health goal (1, 2). Procalcitonin (PCT) is a biomarker of bacterial infection that can enhance identification of patients in whom antibiotics can be safely withheld or duration shortened (3, 4) . Multiple randomized controlled trials have demonstrated that PCT-based algorithms can substantially reduce antibiotic exposure without increasing mortality or infection-related complications (5-9). These have led to clinical practice guidelines suggesting use of PCT to guide antibiotic duration for patients with sepsis or suspected infection (1, 10, 11).
Methods
Study design. We conducted a survey of all acute care short-stay hospitals in the state of Massachusetts in August, 2016 to determine PCT assay availability, whether testing is performed on site or at an outside laboratory, and turnaround time. This study was reviewed by the institutional review board of the University of Massachusetts Medical School and determined not to be human subjects research.
Data collection. We contacted the laboratory of all acute care hospitals in Massachusetts by telephone and asked to speak with the individual who could best answer our inquiry regarding PCT testing. We then asked the following questions: (1) "Is PCT testing available at specified hospital?" (2) "Is the testing performed on site, or are specimens sent to an outside laboratory?" (3) "If performed on site, what is the expected turnaround time for result availability?" and (4) "If specimens are sent to an outside laboratory, which laboratory is used?" We contacted each outside laboratory from question 4 to determine the processing time for the PCT assay.
We hypothesized that hospital characteristics might be associated with the availability of PCT test results. For example, for-profit hospitals may be more likely to perform PCT testing at a send-out laboratory for cost-savings reasons, or hospitals with higher quality ratings (e.g., Centers for Medicare and Medicaid Services [CMS] stars) may be more likely to offer evidence-based testing. Therefore, we collected descriptive data about each hospital (hospital size, profit status, teaching status, affiliation with multihospital system, and star rating) using publicly available information from the CMS Hospital Compare website (https://www.medicare.gov/hospitalcompare/search.html) and from the Massachusetts Center for Health Information and Analysis hospital profile website (http://www.chiamass.gov/ massachusetts-hospitals/).
Data analysis. We computed descriptive statistics, including the number and percentage of hospitals with PCT testing available on site, not available, or performed at an outside laboratory. We compared differences in hospital characteristics on the basis of PCT testing availability using chi-square and t test. All statistical analyses were performed using SPSS version 24.
Results
All 61 of the 61 (100%) acute care hospitals in Massachusetts responded to our survey. PCT analysis was performed on site at 9 hospitals (14.8%), whereas 48 hospitals (78.7%) sent specimens to outside laboratories for PCT testing, and 4 hospitals (6.6%) did not offer testing at all. The turnaround time for PCT assays performed on site was less than 1 to 2 hours at eight of the nine hospitals that performed on-site analysis (13.1% of all hospitals). At one hospital with on-site testing, PCT turnaround time was less than 1 hour for tests performed during the day, but specimens received during the second and third shift took as long as 16 hours due to batching. The turnaround time for PCT assays performed at the 48 hospitals that used outside laboratories varied from 2 to 7 days, including time for transportation.
Hospitals with on-site PCT testing may be more likely to be nonprofit (100 vs. 80.8%, respectively; P = 0.15) and have lower mean CMS star ratings (2.89 vs. 3.23; P = 0.15) than hospitals where PCT testing was not available or was performed by outside Supported by grant 1K08HS024596-01 from the Agency for Health Care Research and Quality (K.A.F.) and grant K24HL132008 from the National Heart. Lung, and Blood Institute of the National Institutes of Health (P.K.L.).
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Comment
Fewer than 20% of acute care hospitals in Massachusetts performed PCT testing on site. This finding is striking given the difference in turnaround time for PCT testing performed on site (,2 hours for most samples) as compared with testing at outside laboratories (2-7 d). In most of the randomized controlled trials demonstrating reduced antibiotic exposure with use of a PCTbased antibiotic algorithm (5-8), PCT testing was performed on site, 7 d/wk, with results available to treating clinicians within 3 hours. By comparison, with turnaround times measured in days as compared with hours at the majority of Massachusetts hospitals, the benefits of PCT-based algorithms on antibiotic initiation and duration is likely to be minimal, as found in recent observational studies (12, 13) . Given the increased duration of antibiotics with PCT use in one observational study (12) , it is also possible that clinicians may inadvertently prolong antibiotics courses while awaiting PCT results at hospitals with long turnaround times.
For most hospital characteristics, we did not find significant differences between hospitals where PCT testing was performed on site as compared with hospitals where it was unavailable or performed at an outside laboratory. Unexpectedly, hospitals that performed PCT testing on site were less likely to be part of a multihospital health system. This finding raises the possibility that decision-making about laboratory test processes may be made centrally, with less opportunity for input from frontline clinicians, at hospitals that are part of a larger system. However, it should be noted that the hospital comparison is an exploratory analysis, limited by small sample size, and these findings should be considered hypothesis generating rather than definitive.
This study has several limitations. Due to the single-state sample, we were unable to assess geographic differences in PCT test performance, and therefore our findings may not be generalizable to all U.S. hospitals. We did not have information about PCT testing rates and were therefore unable to assess for association between on-site availability and usage. Finally, we did not assess other potential barriers that may also contribute to the limited impact of PCT in reducing antibiotic use in routine clinical practice. Such factors may include clinician knowledge of PCT, comfort with antibiotic deescalation, acceptance of PCT-based antibiotic algorithms, as well as institutional normative antibiotic prescribing practices and local antibiotic stewardship programs. However, in the absence of timely PCT test result availability, these barriers are expected to be of lesser consequence.
Despite these limitations, our findings demonstrate that PCT testing in routine clinical practice is not available to clinicians in a manner that would be expected to yield timely results or favorably impact antibiotic prescribing in the majority of hospitals in Massachusetts. Ensuring timely and widely available PCT test results is an important first step toward reaching the currently unrealized (12, 13) potential benefits of PCT-based algorithms for antibiotic stewardship outside of clinical trials. 
